What is the appropriate multidrug therapy for leprosy and what prophylactic measures should a healthcare worker take after exposure to a coughing, untreated leprosy patient?

Leprosy treatment and HCW post-exposure actions

Bolded Recommendation:
Treat multibacillary leprosy with rifampin + clofazimine + dapsone for 12 months, and paucibacillary leprosy with rifampin + dapsone for 6 months; after close respiratory exposure to an untreated, coughing leprosy patient, promptly arrange contact tracing and give single-dose rifampicin post-exposure prophylaxis (SDR-PEP) to eligible close contacts to reduce morbidity, disability, and transmission. 1, 2, 3

1) Definitive multidrug therapy (MDT) for leprosy

• Classify by clinical spectrum (nerve involvement, lesion count, smear if available):

  • Paucibacillary (PB): ≤5 skin lesions, 1 nerve trunk involved, smear negative.
  • Multibacillary (MB): >5 lesions and/or multiple nerves, smear positive.

• Regimens (prioritize preventing nerve damage/disability = QoL, morbidity):

  • PB (6 months):
    • Rifampin + dapsone daily/monthly per standard MDT packs. 1, 2
  • MB (12 months):
    • Rifampin + clofazimine + dapsone daily/monthly per standard MDT packs. 1, 2

• Notes:

  • Monitor for dapsone hemolysis (consider G6PD), rifampin hepatotoxicity, clofazimine skin discoloration/QT risk. [General medicine; clofazimine safety echoed in TB/leprosy experience] 4
  • Alternative monthly RMM (rifampin–moxifloxacin–minocycline) has supportive case-series data but is not guideline-standard; reserve if intolerance/contraindications to MDT. 5

2) What a healthcare worker should do after exposure to a coughing, untreated leprosy patient

• Immediate steps (to protect morbidity, mortality, QoL via transmission interruption and early nerve-sparing treatment):
  1. Risk assessment:
     • Define “close contact”: repeated, prolonged, close proximity (household-like or similar occupational closeness). Respiratory exposure from an untreated MB patient is higher risk. 1
  2. Post-exposure prophylaxis (PEP) for contacts:
     • Offer single-dose rifampicin (SDR-PEP) to eligible close contacts after excluding active TB/leprosy and rifampin contraindications; reduces leprosy by ~57% over first 2 years. 3
     • Coordinate through public health/National Hansen’s Disease Program-equivalent contact tracing. 1, 3
  3. Vaccination:
     • Ensure BCG per local policy in endemic/high-risk settings; protective effect in contacts. 3
  4. Monitoring:
     • Baseline symptom/skin–nerve check; schedule periodic screening for at least 2 years given long incubation; expedite evaluation if any hypoesthetic patches, neuropathic pain, or nerve thickening arise to prevent disability. 1
  5. Work restrictions/PPE:
     • No work exclusion if asymptomatic; use standard precautions. Leprosy is low contagiousness; once patients start MDT, infectivity rapidly declines. [General medicine; supported by leprosy epidemiology] 1
• Pitfalls to avoid:
  • Do not give SDR-PEP if active leprosy or TB is suspected; evaluate first. 3
  • Do not miss neuropathy: test light touch, pain, temperature, vibration in ulnar, posterior tibial, peroneal distributions; check nerve tenderness/thickening. Early steroids for reactions prevent disability. 1

3) Divergences and strength of evidence

• Most recent, high-quality disease primer and WHO-aligned standards support 6-month PB and 12-month MB MDT as the morbidity/QoL–maximizing approach. 1, 2
• SDR-PEP is supported by meta-analytic synthesis and incorporated in WHO practice since 2018; strongest recent evidence for contact chemoprophylaxis to reduce transmission and disability. 3
• RMM monthly regimen shows good tolerability in a small recent case series but lacks guideline endorsement; use only when standard MDT is unsuitable. 5

4) Quick algorithm

• Suspected leprosy patient: classify PB vs MB → start MDT (PB 6 mo; MB 12 mo). 1, 2
• HCW exposure to coughing, untreated patient:
  • Determine close contact status → exclude active disease/contraindications → administer SDR-PEP if eligible → ensure BCG per policy → schedule surveillance for ≥2 years → no routine work exclusion if asymptomatic. 3, 1